These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 1883984)
1. Mechanism of action of isosorbide-5-mononitrate in reducing portal pressure in cirrhotic patients with cirrhosis and portal hypertension. Jenkins SA; Shields R J Gastroenterol Hepatol; 1991; 6(1):91-3. PubMed ID: 1883984 [No Abstract] [Full Text] [Related]
2. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Lin HC; Yang YY; Hou MC; Huang YT; Lee FY; Lee SD Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755 [TBL] [Abstract][Full Text] [Related]
3. Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. Piscaglia F; Donati G; Gaiani S; Gramantieri L; Leoni S; Mancini M; Bolondi L Dig Liver Dis; 2004 Sep; 36(9):594-602. PubMed ID: 15460844 [TBL] [Abstract][Full Text] [Related]
4. Effect and mechanism of action of isosorbide-5-mononitrate. Hayes PC; Westaby D; Williams R Gut; 1988 Jun; 29(6):752-5. PubMed ID: 3384359 [TBL] [Abstract][Full Text] [Related]
5. Effect of peroral administration of isosorbide dinitrate on portal pressure and blood flow in patients with cirrhosis of the liver. Cervinka J; Kordac V; Kalab M J Int Med Res; 1989; 17(6):560-4. PubMed ID: 2628133 [TBL] [Abstract][Full Text] [Related]
6. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis. Escorsell A; Feu F; Bordas JM; García-Pagán JC; Luca A; Bosch J; Rodés J J Hepatol; 1996 Apr; 24(4):423-9. PubMed ID: 8738728 [TBL] [Abstract][Full Text] [Related]
7. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Morillas RM; Planas R; Cabré E; Galán A; Quer JC; Feu F; García Pagán JC; Bosch J; Gassull MA Hepatology; 1994 Dec; 20(6):1502-8. PubMed ID: 7982651 [TBL] [Abstract][Full Text] [Related]
8. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. Villanueva C; López-Balaguer JM; Aracil C; Kolle L; González B; Miñana J; Soriano G; Guarner C; Balanzó J J Hepatol; 2004 May; 40(5):757-65. PubMed ID: 15094222 [TBL] [Abstract][Full Text] [Related]
9. Duplex Doppler sonographic evaluation of splanchnic and renal effects of single agent and combined therapy with nadolol and isosorbide-5-mononitrate in cirrhotic patients. Bolognesi M; Sacerdoti D; Merkel C; Gatta A J Ultrasound Med; 1994 Dec; 13(12):945-52. PubMed ID: 7877205 [TBL] [Abstract][Full Text] [Related]
10. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Garcia-Pagán JC; Navasa M; Bosch J; Bru C; Pizcueta P; Rodés J Hepatology; 1990 Feb; 11(2):230-8. PubMed ID: 2307401 [TBL] [Abstract][Full Text] [Related]
11. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. García-Pagán JC; Feu F; Bosch J; Rodés J Ann Intern Med; 1991 May; 114(10):869-73. PubMed ID: 2014947 [TBL] [Abstract][Full Text] [Related]
12. The effect of a combined treatment with propranolol and isosorbide-5-mononitrate on Doppler ultrasound parameters in patients with cirrhosis and portal hypertension. Orban Schiopu AM; Balas BI; Diculescu M Rom J Gastroenterol; 2005 Jun; 14(2):123-7. PubMed ID: 15990930 [TBL] [Abstract][Full Text] [Related]
13. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Navasa M; Chesta J; Bosch J; Rodés J Gastroenterology; 1989 Apr; 96(4):1110-8. PubMed ID: 2925055 [TBL] [Abstract][Full Text] [Related]
14. Duplex Doppler ultrasonographic comparison of the effects of propranolol and isosorbide-5-mononitrate on portal hemodynamics. Tincani E; Cioni G; Cristani A; D'Alimonte P; Vignoli A; Abbati G; Ventura P; Romagnoli R; Ventura E J Ultrasound Med; 1993 Sep; 12(9):525-9. PubMed ID: 8107184 [TBL] [Abstract][Full Text] [Related]
15. Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin. Hallemans R; Naeije R; Mols P; Mélot C; Reding P Crit Care Med; 1983 Jul; 11(7):536-40. PubMed ID: 6861502 [TBL] [Abstract][Full Text] [Related]
16. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis. Grose RD; Plevris JN; Redhead DN; Bouchier IA; Hayes PC J Hepatol; 1994 Apr; 20(4):542-7. PubMed ID: 8051395 [TBL] [Abstract][Full Text] [Related]
17. Effect of sublingual isosorbide dinitrate on wedged hepatic venous pressure in cirrhotics with portal hypertension. Qureshi H; Zuberi SJ; Faruqui A Indian J Gastroenterol; 1988 Jul; 7(3):161-2. PubMed ID: 3397139 [No Abstract] [Full Text] [Related]
18. Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis. Freeman JG; Barton JR; Record CO Br Med J (Clin Res Ed); 1985 Aug; 291(6495):561-2. PubMed ID: 3929873 [TBL] [Abstract][Full Text] [Related]
19. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Merkel C; Sacerdoti D; Bolognesi M; Enzo E; Marin R; Bombonato G; Angeli P; Gatta A Hepatology; 1997 Jul; 26(1):34-9. PubMed ID: 9214449 [TBL] [Abstract][Full Text] [Related]
20. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. García-Pagán JC; Feu F; Navasa M; Bru C; Ruiz del Arbol L; Bosch J; Rodés J J Hepatol; 1990 Sep; 11(2):189-95. PubMed ID: 2123914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]